Walleye Capital
INDV icon

Walleye Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Walleye Capital’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,664
Closed -$538K – 4940
2026
Q1 		$538K Sell
17,664
-229,724
-93% -$7.59M ﹤0.01% 2610
2025
Q4 		$8.88M Sell
247,388
-196,362
-44% -$6M 0.03% 741
2025
Q3 		$10.7M Buy
443,750
+403,482
+1,002% +$8.44M 0.04% 508
2025
Q2 		$594K Buy
+40,268
New +$469K ﹤0.01% 2494

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's INDV Position: Q2 2026 in Review

Walleye Capital sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 17,664 shares — an estimated $538K sold.

Walleye Capital first reported a position in INDV in Q2 2025 and held it in 4 quarters. The position peaked at $10.7M in Q3 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Walleye Capital reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 17,664 Indivior Pharmaceuticals shares in Q2 2026, an estimated $538K.
  • Walleye Capital first reported a position in Indivior Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Walleye Capital's Indivior Pharmaceuticals position peaked at $10.7M in Q3 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.